Skip to content

Predictors of Response to Treatment for Depression

Neural Predictors of Response to Cognitive Behavioral Therapy for Adolescent Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03154008
Acronym
PORT
Enrollment
70
Registered
2017-05-15
Start date
2017-06-01
Completion date
2020-06-08
Last updated
2020-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Depression, Depression

Keywords

reward, emotion regulation, electroencephalogram, event-related potentials, cognitive behavior therapy

Brief summary

The current study will examine neurophysiological, specifically event-related potential (ERP), measures of emotional processing as predictors of response to cognitive behavior therapy for adolescent depression.

Detailed description

Neurophysiological measures (i.e., event-related potentials) of reward responsiveness and regulation of mood-congruent, sad stimuli will be assessed in a sample of adolescents with depression prior to group cognitive behavior therapy (CBT). CBT will follow the Adolescent Coping with Depression Course, an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention. Changes in symptoms will be monitored through biweekly self-report and clinician ratings to examine prediction of change in symptoms across CBT. Baseline individual differences in reward responsiveness and emotion regulation will be evaluated as predictors of change in self-reported symptoms and clinician-rated improvement following CBT.

Interventions

BEHAVIORALCognitive Behavioral Therapy

Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.

Sponsors

The Klingenstein Third Generation Foundation
CollaboratorOTHER
Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Participants presenting with major depressive or persistent depressive disorder and moderate severity on the Clinical Global Impressions scale. * Participants may have comorbid externalizing or anxiety disorders. * Participants (and parents of minors) fluent in English.

Exclusion criteria

* Youth with history of treatment for substance use disorders. * Youth with intellectual or developmental disabilities (e.g., autism spectrum disorders, pervasive developmental disorders). * Youth with lifetime schizophrenia, psychosis, or mania. * Youth with severe current suicidality. * Youth taking antipsychotic medications or mood stabilizers. * Youth with recent changes in dosage of antidepressant (adolescents with change in dosage in past 30 days who otherwise meet study criteria will be asked to begin the study once dosage has been stable for 30 days). * Parent or child not fluent in English. * Youth who are unable to complete study procedures because of visual or hearing impairments. * Youth who have recently started outside therapy (past 30 days at time of intake), are engaged in treatment that is determined to be too similar to study therapy (e.g, other CBT groups), or are currently in treatment that is too intensive to allow for participation in study therapy (e.g., partial hospitalization programs)

Design outcomes

Primary

MeasureTime frameDescription
Depressive symptomspast 2 weeksSelf-reported symptoms on the Mood and Feelings Questionnaire
Clinician-rated improvement8 weeksGlobal improvement rating on the Clinical Global Impression scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026